Recce Pharmaceuticals Ltd (RCE.AX)

0,6500 +0,0100 (+1,56%) Börsenschluss: 04:10PM AEST

Recce Pharmaceuticals Ltd

Level 23, 180 George Street
Salesforce Tower
Sydney, NSW 2000
Australia
61 2 9256 2505
https://www.recce.com.au

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. John K. A. Prendergast Ph.D.	Executive Chairman of the Board	369,85k	N/A	1954
Mr. James Hamilton-Bray Graham GAICD	CEO, MD & Executive Director	774,73k	N/A	N/A
Ms. Michele Keryn Diliza BA (Journ), BSc (Med Sci)	Chief Scientific Director & Executive Director	539,34k	N/A	N/A
Dr. Justin Ward	Principal Quality Chemist & Executive Director	306,76k	N/A	N/A
Mr. Arthur Kollaras	Principal Engineer & Head of Manufacturing	319,12k	N/A	N/A
Dr. Alan W. Dunton B.Sc., M.D.	Chief Medical Advisor & Independent Non Executive Director	72,5k	N/A	1954
Mr. Justin Reynolds	Chief Financial Officer	N/A	N/A	N/A
Mr. Daniel Astudillo B.A., B.Com., M.B.A.	Head of Marketing	N/A	N/A	N/A
Ms. Maggie Niewidok	Company Secretary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in AUD.

Beschreibung

Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use. In addition, the company engages in R327 Intravenous which provides serious/life-threatening bacterial infections, including sepsis which is in the phase 1 trial; urinary tract infections, including urosepsis; rapid infusions sepsis in the phase 2 trial; and R327 Topical offers wound infections, including infected burns; and diabetic foot ulcer infections in Phase 2 trails. Further, the company operates various pre-clinical programs, such as Mycobacterium abscessus which is in phase 1 clinical trial; bacterial sinusitis; and additional TBA. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Corporate Governance

Recce Pharmaceuticals Ltds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.